# European Trial About Effect of RimoNabant on Abdominal Obese Patients With dysLipidemia

> **NCT00412698** · PHASE3 · TERMINATED · sponsor: **Sanofi** · enrollment: 645 (actual)

## Conditions studied

- Obesity
- Dyslipidemias

## Interventions

- **DRUG:** rimonabant
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00412698
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2006-12
- **Primary completion:** 2009-01
- **Final completion:** 2009-01
- **Target enrollment:** 645 (ACTUAL)
- **Why stopped:** Company decision has been taken in light of recent demands by certain national health authorities
- **Last updated:** 2010-12-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00412698

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00412698, "European Trial About Effect of RimoNabant on Abdominal Obese Patients With dysLipidemia". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT00412698. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*